Funding for this research was provided by:
Health Innovation, Investment and Research Office (QCHO/009948)
Received: 12 June 2020
Accepted: 31 July 2020
First Online: 30 September 2020
Ethics approval and consent to participate
: The trial received ethics approval from the Griffith University (GU Ref No: 2016/052) and the Royal Brisbane and Women’s Hospital (HREC/15/QRBWH/592) Human Research Ethics Committees. Given the intervention was a reiteration of current practice recommendations and included already licenced products, no new practice was introduced and no treatment was being withheld; the ethics committees granted a waiver of consent due to the low/negligible risk associated with the trial. Patients were given information sheets about the study being conducted on the ward and had the ability to opt out if they wished.
: Not applicable.
: SK’s current employer (QUT) has received on her behalf education consultancy fees from BD Medical. NM’s previous employer (Griffith University) has received on her behalf investigator-initiated research grants and unrestricted educational grants from BD-Bard and Cardinal Health consultancy fees from BD-Bard. CMR’s employer has received, on her behalf, investigator-initiated research grants and unrestricted educational grants from BD-Bard, Cardinal Health, and consultancy fees from 3 M, BD-Bard, BBraun. All other authors declare no competing interests. BD Medical provided in-kind support for this study through the provision of product education. BD Medical did not design the study protocol, did not collect or analyse data, and were not involved at all in the preparation of the manuscript. There are no non-financial competing interests to declare.